Predicting Wound Healing Complications in the Emergency Department

预测急诊科的伤口愈合并发症

基本信息

  • 批准号:
    7383463
  • 负责人:
  • 金额:
    $ 20.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-15 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In 2003 there were 114 million emergency department visits, of which 5.7 percent involved the treatment of acute open wounds. In general there is a lack of clinical outcomes research to determine the most efficient method to treat these wounds. Current treatment of acute wounds is guided by old dogma, some of which may not be appropriate. Evidence is based on animal trials and on old clinical research lacking sufficient methods or in fact non-existent and perpetuated by opinion. A classic example is the treatment of hand lacerations and the rate of wound infections from dog bites, both studied in the candidate's K-23 award. Old literature suggests the baseline infection rates for dog bites is about 15 percent overall and perhaps as high as 30 percent for hand wounds leading to many advocating for prophylactic antibiotics. Current work suggests that the current rate of infection is probably 5 percent making the rationale to treat all wounds invalid. The candidate has also challenged dogma demonstrating that simple hand lacerations heal regardless of whether they are treated with sutures or conservatively. The majority of acute wounds are simple and uncomplicated that only occasionally may develop complications such as infection and dehiscence. There are tremendous variations in wound care practices among physicians. This includes wound cleansing (what solution and how much irrigation?), wound closure (primary vs. secondary and modality), and the use of prophylactic antibiotics. Determining which wounds are at risk for complications based on outcomes research will guide treatment and follow-up decisions and ultimately allow for the most cost-effective care. The candidate has expertise in the area of wound care and has completed extra graduate training in clinical research. Having successfully completed his K-23 award the candidate has prepared himself for a career as an independent clinical scientist .The purpose of the proposed application is to allow the candidate to utilize his research skills in clinical decision rule development and his passion for wound care research to develop clinical decision guidelines to predict wounds at risk for complications after ED treatment. The specific aim of this application is to utilize the wound care network established in the candidate's K-23 to collect a large prospective cohort of lacerations and acute dog bite wounds to develop a decision rule to predict wound healing complications. Using his real-time notification and tracking system to identify eligible patients, he will have physicians prospectively complete a standardized web based data collection form. He will then determine wound outcomes (infection and dehiscence) within 30 days to determine the rates of acute wound complications. Using his skills in clinical prediction rule development specifically utilizing recursive partitioning techniques he will derive highly sensitive and specific clinical prediction rules for predicting complications of acute lacerations and dog bite wounds. If the candidate can successfully derive the rules in this R-21 they will be subsequently validated and implemented to improve the efficiency of acute wound care. This application will study the second most common reason why people seek medical care in the country, the treatment of acute traumatic lacerations and bites. The potential impact of this study is enormous as the study results will guide efficient and cost effective management decisions on controversial issues such as which patients would benefit from prophylactic antibiotics. This will be accomplished by studying a large group of patients presenting to emergency departments with acute lacerations and dog bites to determine the current incidence of wound complications, primarily infection. Numerous variables will then be analyzed to determine a group of risk factors for developing these complications. Knowing which patients are at risk for complications will help guide treatment and management decisions.
描述(由申请人提供):2003年,有1.14亿次急诊就诊,其中5.7%涉及急性开放性伤口的治疗。一般来说,缺乏临床结果研究来确定治疗这些伤口的最有效方法。目前急性伤口的治疗是由旧的教条指导的,其中一些可能是不合适的。证据是基于动物试验和旧的临床研究,缺乏足够的方法或事实上不存在,并通过意见延续。一个经典的例子是手部撕裂伤的治疗和狗咬伤伤口感染的发生率,这两个问题都在候选人的K-23奖中得到了研究。旧的文献表明,狗咬伤的基线感染率约为15%,手部伤口的感染率可能高达30%,这导致许多人主张使用预防性抗生素。目前的工作表明,目前的感染率可能是5%,使治疗所有伤口的理由无效。这位候选人还挑战了教条,证明简单的手部撕裂伤可以愈合,无论是缝合还是保守治疗。大多数急性伤口都很简单,不复杂,只是偶尔会出现感染和裂开等并发症。医生之间的伤口护理实践存在巨大差异。这包括伤口清洗(什么溶液和多少冲洗?),伤口闭合(主要与次要和模态),以及预防性抗生素的使用。根据结果研究确定哪些伤口有并发症的风险,将指导治疗和后续决策,并最终实现最具成本效益的护理。候选人在伤口护理领域具有专业知识,并已完成临床研究方面的额外研究生培训。成功完成K-23奖后,候选人已经为自己作为独立临床科学家的职业生涯做好了准备。拟议申请的目的是让候选人利用他在临床决策规则开发方面的研究技能和他对伤口护理研究的热情来开发临床决策指南,以预测艾德治疗后并发症的风险。本申请的具体目的是利用在候选人的K-23中建立的伤口护理网络来收集撕裂伤和急性狗咬伤伤口的大型前瞻性队列,以开发预测伤口愈合并发症的决策规则。利用他的实时通知和跟踪系统来识别符合条件的患者,他将让医生前瞻性地完成一个标准化的基于网络的数据收集表格。然后,他将在30天内确定伤口结局(感染和裂开),以确定急性伤口并发症的发生率。利用他在临床预测规则开发方面的技能,特别是利用递归分区技术,他将获得高度敏感和具体的临床预测规则,用于预测急性撕裂伤和狗咬伤的并发症。如果候选人能够成功推导出R-21中的规则,则随后将对其进行验证和实施,以提高急性伤口护理的效率。 该应用程序将研究人们在该国寻求医疗护理的第二个最常见的原因,即急性创伤性撕裂伤和咬伤的治疗。这项研究的潜在影响是巨大的,因为研究结果将指导有争议的问题,如哪些患者将受益于预防性抗生素的有效和成本效益的管理决策。这将通过研究一大群因急性撕裂伤和狗咬伤而到急诊室就诊的患者来完成,以确定伤口并发症(主要是感染)的当前发生率。然后将分析许多变量,以确定发展这些并发症的一组风险因素。了解哪些患者有并发症的风险将有助于指导治疗和管理决策。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James V. Quinn其他文献

Outcomes in syncope research: a systematic review and critical appraisal
  • DOI:
    10.1007/s11739-018-1788-z
  • 发表时间:
    2018-01-18
  • 期刊:
  • 影响因子:
    3.800
  • 作者:
    Monica Solbiati;Viviana Bozzano;Franca Barbic;Giovanni Casazza;Franca Dipaola;James V. Quinn;Matthew J. Reed;Robert S. Sheldon;Win-Kuang Shen;Benjamin C. Sun;Venkatesh Thiruganasambandamoorthy;Raffaello Furlan;Giorgio Costantino
  • 通讯作者:
    Giorgio Costantino
An Underrecognized Cause of Recurrent Nocturnal Syncope with a Pacemaker: Sleep Rate Mode
  • DOI:
    10.1016/j.jemermed.2023.03.055
  • 发表时间:
    2023-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jonathan D. Woo;James V. Quinn
  • 通讯作者:
    James V. Quinn

James V. Quinn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James V. Quinn', 18)}}的其他基金

Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    8399109
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    8536958
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    8702243
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    8133341
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    7255269
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    7924231
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Predicting Wound Healing Complications in the Emergency Department
预测急诊科的伤口愈合并发症
  • 批准号:
    7497616
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    7503413
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
Stanford University Hub for Neurological Emergency Treatment Trials
斯坦福大学神经紧急治疗试验中心
  • 批准号:
    7676781
  • 财政年份:
    2007
  • 资助金额:
    $ 20.38万
  • 项目类别:
A NETWORK OF RESEARCH UNITS TO STUDY CLINICAL WOUND CARE
研究临床伤口护理的研究单位网络
  • 批准号:
    6632713
  • 财政年份:
    2000
  • 资助金额:
    $ 20.38万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 20.38万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了